Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Development and Immunohistochemical Characterization of Patient-Derived Xenograft Models for Muscle Invasive Bladder Cancer Publisher



Razzaghdoust A1 ; Muhammadnejad S2 ; Parvin M3 ; Mofid B4 ; Zangeneh M5 ; Basiri A1
Authors

Source: Iranian Journal of Basic Medical Sciences Published:2021


Abstract

Objective(s): Patient-derived xenograft (PDX) models have become a valuable tool to evaluate chemotherapeutics and investigate personalized cancer treatment options. The role of PDXs in the study of bladder cancer, especially for improvement of novel targeted therapies, continues to expand. In this study, we aimed to establish autochthonous PDX models of muscle-invasive bladder cancer (MIBC) to provide a useful tool to conduct research on personalized therapy. Materials and Methods: Tumors from MIBC patients undergoing radical cystectomy were subcutaneously transplanted into immunodeficient mice. The tumor size was measured by a caliper twice a week for up to five months. After the first growth in mice, they were serially passaged. Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) of 11 markers (Ki67, P63, GATA3, KRT5/6, KRT20, E-cadherin, 34βE12, PD-L1, EGFR, Nectin4, and HER2) were used to evaluate phenotype maintenance of original tumors. Results: From 10 MIBC patients, two PDX models (P8X20 and P8X26) were successfully established (20% success rate). These models mostly retained primary tumor characteristics including histology, morphology, and molecular nature of the original cancer tissues. IHC analysis showed that the expression level of 7 markers for the model P8X20, and 8 markers for the model P8X26 was exactly similar between the patient tumor and the next generations. Conclusion: We developed the first autochthonous PDX models of MIBC in Iran. Our data suggested that the established MIBC PDX models reserved mostly histopathological characteristics of primary cancer and could provide a new tool to evaluate novel biomarkers, therapeutic targets, and drug combinations. © 2021 Mashhad University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Patient-Derived Xenograft (Pdx) Models, Applications and Challenges in Cancer Research, Journal of Translational Medicine (2022)
2. Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor, European Journal of Pharmacology (2020)
3. Combination of T-Dm1 and Platinum-Based Chemotherapy in Patient-Derived Xenograft Models of Muscle-Invasive Bladder Cancer, Iranian Journal of Basic Medical Sciences (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Nowroozi (3)
Mehdi Kardoost Parizi (3)
Other Related Docs
4. The Value of Epidermal Growth Factor Receptor Expression in Predicting Aggressive Behaviors of Bladder Neoplasms, Nephro-Urology Monthly (2023)
5. Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions, Applied Sciences (Switzerland) (2020)
6. Evaluation of Direct Intramural Injection to the Bladder Wall As a Method for Developing Orthotopic Tumor Models, Animal Models and Experimental Medicine (2022)
7. Role of Lncrna Pvt1 in the Progression of Urological Cancers: Novel Insights Into Signaling Pathways and Clinical Opportunities, Cellular Signalling (2025)
8. Human Umbilical Cord Mesenchymal Stem Cells-Derived Extracellular Vesicles As a Therapeutic Approach to Ameliorate Bladder Injury in Animal Models of Radiation Cystitis, Stem Cell Research and Therapy (2025)
9. Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study, Clinical Genitourinary Cancer (2023)
10. Evaluation of Igf2, Krt14, and Krt20 As Urinary Biomarkers in Patients With Bladder Cancer, Reports of Biochemistry and Molecular Biology (2023)
11. Immunotherapy in Bladder and Renal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
12. Trimodality Therapy Versus Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Matched Cohort Studies, European Urology Focus (2024)
13. High Resolution Melting Analysis for Rapid Detection of Pik3ca Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy, Urology Journal (2018)
14. Molecular Biology, Genetic, and Epigenetics of Bladder Tumor, (2024)
15. Fibroblast Growth Factor Receptor: A Systematic Review and Meta-Analysis of Prognostic Value and Therapeutic Options in Patients With Urothelial Bladder Carcinoma, Urologic Oncology: Seminars and Original Investigations (2021)
16. The Value and Limitations of Urothelial Bladder Carcinoma Molecular Classifications to Predict Oncological Outcomes and Cancer Treatment Response: A Systematic Review and Meta-Analysis, Urologic Oncology: Seminars and Original Investigations (2021)
17. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
18. The Incidence and Prognostic Role of Β-Catenin and E-Cadherin Biomarkers in Bladder Neoplasms, a Cross-Sectional Study, International Journal of Surgery Open (2023)
19. Differential Expression of Fgfrs Signaling Pathway Components in Bladder Cancer: A Step Toward Personalized Medicine, Balkan Journal of Medical Genetics (2017)
20. The Progressive Trend of Modeling and Drug Screening Systems of Breast Cancer Bone Metastasis, Journal of Biological Engineering (2024)